Brief: Verrica Pharmaceuticals Announces Start Of Phase 3 Trial Of VP-102 For The Treatment Of Molluscum Contagiosum By Torii Pharmaceutical Co In Japan
01/08/2022 12:39
Aug 1 (Reuters) - Verrica Pharmaceuticals Inc VRCA.O :
* VERRICA PHARMACEUTICALS ANNOUNCES START OF PHASE 3 TRIAL
OF
VP-102 FOR THE TREATMENT OF MOLLUSCUM CONTAGIOSUM BY TORII
PHARMACEUTICAL CO., LTD. IN JAPAN
* VERRICA PHARMACEUTICALS INC- TORII PHARMACEUTICAL CO DOSED
FIRST
PATIENT IN ITS PHASE 3 TRIAL OF VP-102 FOR MOLLUSCUM CONTAGIOSUM
IN JAPAN
* VERRICA PHARMACEUTICALS INC - COMPANY EARNS $8 MILLION
PHASE 3
MILESTONE PAYMENT
Source text for Eikon: ID:nGNX70P59f
Further company coverage: VRCA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Verrica Pharmaceuticals
See all newsVerrica Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Verrica Pharma reports wider-than-expected Q2 adj loss per share
Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Verrica Pharmaceuticals Q1 revenue rises on YCANTH demand
Brief: Verrica Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Data